Strategy focuses on developing and commercializing a differentiated pipeline of highly innovative oncology assets addressing unmet needs Helsinn intends to reinvest approximately 35% of revenues […]

Lugano, Switzerland, December 21, 2021 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong […]

Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group (Helsinn), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care […]

Per la versione in italiano, vogliate seguire questo link. Lugano, Switzerland, December 6, 2021 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with […]

Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global biopharmacompany with a diversified pipeline of innovative oncology assets and strong track-record ofcommercial […]

The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4)has the potential to impact approximately 500,000 cancer patients with unmet therapeuticneeds BridgeBio and Helsinn […]

Lugano, Switzerland – Shanghai, China, October 12, 2021 – Helsinn Group (“Helsinn”), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care […]

– Health Canada Issues Conditional Approval of TRUSELTIQ under Project Orbis (September 27th, 2021) LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 – Helsinn […]

Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing […]

Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring […]